This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any medication.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. While semaglutide targets GLP-1 alone and tirzepatide targets GLP-1 and GIP, retatrutide adds glucagon receptor agonism — creating a three-pronged approach to metabolic regulation. This makes it the first triple incretin to reach late-stage clinical development.
The addition of glucagon receptor activity is pharmacologically significant: glucagon promotes hepatic glycogenolysis and gluconeogenesis, stimulates lipolysis and thermogenesis in adipose tissue, and increases energy expenditure. The combination of appetite suppression (GLP-1/GIP) with increased energy expenditure (glucagon) creates a dual mechanism for energy balance that no previous drug has achieved.
Mechanism of Action
Each receptor target contributes distinct metabolic effects:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, enhances insulin secretion, and activates central satiety circuits.
- GIP receptor: Improves insulin sensitivity, enhances fat metabolism, and may attenuate GLP-1-mediated nausea.
- Glucagon receptor: Increases hepatic lipid oxidation, stimulates thermogenesis, raises resting energy expenditure, and promotes lipolysis. Glucagon agonism also appears to reduce hepatic fat content, which is significant for MASLD/NASH treatment.
The theoretical concern with glucagon agonism — hyperglycemia — appears to be mitigated by the concurrent GLP-1 and GIP activity, which enhance insulin secretion and glucose disposal sufficiently to counterbalance glucagon's glycogenolytic effects.
Phase 2 Clinical Trial Results
The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity. Results at 48 weeks were remarkable: participants on the highest dose (12 mg) achieved an average weight loss of 24.2% of body weight — the highest ever reported for a pharmacological intervention in a controlled trial at that time. At the 12 mg dose, 26% of participants lost more than 30% of body weight.
The weight loss trajectory had not plateaued at 48 weeks, suggesting even greater reductions might occur with longer treatment. Retatrutide also produced significant reductions in waist circumference, blood pressure, triglycerides, and fasting glucose levels. A sub-study using MRI showed a remarkable 82% relative reduction in liver fat content, with over 85% of participants with baseline MASLD achieving normalization.
Safety Profile
Gastrointestinal events were the most common adverse effects: nausea (22-26% at higher doses), diarrhea (20-22%), vomiting (9-13%), and constipation. Most GI events occurred during dose escalation and attenuated over time. No significant safety signals for pancreatitis, thyroid events, or cardiovascular adverse events were observed, though the trial was not powered to detect rare events. Heart rate increased modestly (3-4 bpm), consistent with the class effect of incretin agonists.
Critically, concerns about glucagon-induced hyperglycemia were not realized — glucose and HbA1c levels improved across all dose groups. Phase 3 trials (TRIUMPH program) are underway and will provide larger safety datasets.
The Bottom Line
Retatrutide's triple agonist approach represents the cutting edge of incretin-based metabolic therapy, with Phase 2 results showing the most impressive weight loss and liver fat reduction ever reported for a pharmaceutical agent. The addition of glucagon agonism appears to provide meaningful incremental benefit over dual GLP-1/GIP agonism. It is still an investigational drug in Phase 3 trials and is not yet approved for any clinical use.